The late stage of optic pathway glioma is mainly based on the location of the tumor, patient’s age and whether it is accompanied by neurofibromatosis type I (NF1) to choose the treatment, which mainly includes chemotherapy, surgical treatment, targeted therapy and so on.
1. Tumor located in the anterior optic pathway: For asymptomatic or minimally symptomatic patients, observation and follow-up can be performed to monitor the progression of the lesion through serial MRI scans and neuro-ophthalmologic examinations.
If there is progression of the disease or the lesion leads to ocular protrusion and significant vision loss, chemotherapy is preferred. Commonly used chemotherapy regimens include vincristine and actinomycin D. If there is further progression of the disease and the affected eye becomes blind, surgical treatment should be carried out, such as removal of the eyeball.
2. Tumor located in the optic cross and hypothalamus: If the patient is accompanied by NF1 and has not yet developed significant visual field defects, the patient can be followed up for observation. If the patient shows disease progression or obvious visual impairment, chemotherapy is feasible, and targeted therapy with drugs such as Simertinib can also be considered.
In patients who do not have NF1, a biopsy is usually required to determine whether the optic pathway glioma is a hairy cell astrocytoma or another type of tumor. Chemotherapy is usually preferred for children under ten years of age with symptomatic hairy cell astrocytomas, while chemotherapy or radiation therapy is used primarily for older patients.
It is recommended that patients with advanced gliomas of the optic pathway seek medical attention to evaluate their condition and select the appropriate treatment under the guidance of their physician.